Carlsmed Raises $52.5M in Series C Funding


Carlsmed, a Carlsbad, CA-based AI-enabled personalized surgery medtech company, raised $52.5M in Series C funding.

The round was led by B Capital and U.S. Venture Partners.

Led by CEO Mike Cordonnier, Carlsmed has developed the aprevo® personalized surgery platform, which is designed to advance the standard of care for spine surgery one patient at a time.

The company intends to use the funds to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, which will launch in 2025.

Commenting on the news, Mike Cordonnier said: “Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.”